Modality
mAb
MOA
PI3Ki
Target
GLP-1R
Pathway
Apoptosis
NB
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
Apr 2021
→ Jan 2029
Phase 1Current
NCT05848076
1,111 pts·NB
2021-04→2029-01·Recruiting
1,111 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-152.8y awayPh2 Data· NB
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P1/2
Recruit…
Catalysts
Ph2 Data
2029-01-15 · 2.8y away
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05848076 | Phase 1/2 | NB | Recruiting | 1111 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Mavuglumide | Bayer | Approved | GLP-1R |